An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Iveric Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
IVERIC bio (NASDAQ: ISEE) announced that President Pravin U. Dugel, M.D., will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The on-demand presentation will be accessible starting September 13 at 7:00 a.m. ET via the Company’s website. IVERIC bio focuses on developing treatments for retinal diseases, particularly age-related and inherited conditions. An archived replay will be available for at least 30 days post-conference.
Positive
None.
Negative
None.
NEW YORK--(BUSINESS WIRE)--
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will present an overview of the Company at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually from September 13-15, 2021.
The on-demand presentation will be available for viewing beginning September 13 at 7:00 a.m. ET and can be accessed on the Investor / Events & Presentations section of the Iveric Bio website at www.ivericbio.com. An archived replay of the presentation will be available on the Company’s website immediately following the conference and for at least 30 days thereafter.
About Iveric Bio
Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. For more information on the Company, please visit www.ivericbio.com.
Forward-looking Statements
Any statements in this press release or made during the presentation referenced herein about Iveric Bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those described in the “Risk Factors” section of public filings made by Iveric Bio with the U.S. Securities and Exchange Commission. Any forward-looking statements represent Iveric Bio’s views only as of the date of this press release or the presentation, as applicable. Iveric Bio anticipates that subsequent events and developments may cause its views to change. While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so unless required by law.
